- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting
KRAS
mutant lung cancer: light at the end of the tunnel
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-12-24
DOI
10.1002/1878-0261.13168
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Resistance to KRASG12C Inhibitors
- (2021) Victoria Dunnett-Kane et al. Cancers
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression
- (2021) Manuel Sanclemente et al. CANCER CELL
- Cell-type Specific Adaptive Signaling Responses to KRASG12C inhibition
- (2021) Eric B Haura et al. CLINICAL CANCER RESEARCH
- Targeting KRAS: The Elephant in the Room of Epithelial Cancers
- (2021) Valeria Merz et al. Frontiers in Oncology
- The Ins and Outs of RAS Effector Complexes
- (2021) Christina Kiel et al. Biomolecules
- KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments
- (2021) Takamasa Koga et al. Journal of Thoracic Oncology
- The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
- (2021) David M. Briere et al. MOLECULAR CANCER THERAPEUTICS
- Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib
- (2021) Robert Galvin et al. Current Oncology Reports
- Selective and noncovalent targeting of RAS mutants for inhibition and degradation
- (2021) Kai Wen Teng et al. Nature Communications
- Mechanisms of Resistance to KRASG12C-Targeted Therapy
- (2021) Neal S. Akhave et al. Cancer Discovery
- Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
- (2021) Aoife A. Nolan et al. Genes
- The promise and peril of KRAS G12C inhibitors
- (2021) Amanda R. Moore et al. CANCER CELL
- A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
- (2021) Zhiwei Liu et al. MOLECULAR CELL
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Finally, Effective Inhibitors of Mutant KRAS
- (2021) Neal Rosen NEW ENGLAND JOURNAL OF MEDICINE
- KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform
- (2021) Marina Salmón et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drugging the Undruggable: Advances on RAS Targeting in Cancer
- (2021) Miriam Molina-Arcas et al. Genes
- Folding and Stability of Ankyrin Repeats Control Biological Protein Function
- (2021) Amit Kumar et al. Biomolecules
- The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
- (2021) J. Nathaniel Diehl et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
- (2020) Aaron C. Tan Thoracic Cancer
- Current Advances in the Treatment of BRAF-Mutant Melanoma
- (2020) Hima Patel et al. Cancers
- Targeting the MAPK Pathway in KRAS-Driven Tumors
- (2020) Matthias Drosten et al. CANCER CELL
- The Frequency of Ras Mutations in Cancer
- (2020) Ian A. Prior et al. CANCER RESEARCH
- Current therapy of KRAS-mutant lung cancer
- (2020) Aron Ghimessy et al. CANCER AND METASTASIS REVIEWS
- Small molecule inhibitors of RAS proteins with oncogenic mutations
- (2020) Zoltán Orgován et al. CANCER AND METASTASIS REVIEWS
- Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
- (2020) Michael A. Gillette et al. CELL
- Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
- (2020) Marco Jost et al. MOLECULAR CELL
- A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent
- (2020) Stacey J. Baker et al. MOLECULAR CELL
- A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
- (2020) Nicolas Bery et al. Nature Communications
- An in vivo KRAS allelic series reveals distinct phenotypes of common oncogenic variants
- (2020) Maria Paz Zafra et al. Cancer Discovery
- Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities
- (2020) Marcus Robert Kelly et al. Cancer Discovery
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Inhibition of RAS: proven and potential vulnerabilities
- (2020) Mariyam Zuberi et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
- (2020) Dongsung Kim et al. CELL
- Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
- (2020) Yuta Adachi et al. CLINICAL CANCER RESEARCH
- SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
- (2020) Carmine Fedele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas
- (2020) Laura Esteban-Burgos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
- (2020) Marco H Hofmann et al. Cancer Discovery
- SOS GEFs in health and disease
- (2020) Fernando C. Baltanás et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Targeting Alterations in the RAF–MEK Pathway
- (2019) Rona Yaeger et al. Cancer Discovery
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the ERK Signaling Pathway in Melanoma
- (2019) Paola Savoia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
- (2019) María Teresa Blasco et al. CANCER CELL
- Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
- (2019) Miriam Molina-Arcas et al. Science Translational Medicine
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- c-RAF Ablation Induces Regression of Advanced Kras/Trp 53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
- (2018) Manuel Sanclemente et al. CANCER CELL
- KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
- (2018) Chiara Ambrogio et al. CELL
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Afatinib restrains K-RAS–driven lung tumorigenesis
- (2018) Herwig P. Moll et al. Science Translational Medicine
- The ERBB network facilitates KRAS-driven lung tumorigenesis
- (2018) Björn Kruspig et al. Science Translational Medicine
- Targeting the MAPK Pathway in RAS Mutant Cancers
- (2018) Sarah G. Hymowitz et al. Cold Spring Harbor Perspectives in Medicine
- Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
- (2018) Camilo E. Quevedo et al. Nature Communications
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
- (2017) Yaohua Xue et al. NATURE MEDICINE
- RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα
- (2017) Andrea Varga et al. Science Signaling
- Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets
- (2017) Matthias Drosten et al. Cold Spring Harbor Perspectives in Medicine
- RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα
- (2017) Andrea Varga et al. Science Signaling
- H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences
- (2016) Matthias Drosten et al. CANCER RESEARCH
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
- (2016) Alex Kim et al. Expert Opinion on Drug Discovery
- Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
- (2016) Chiara Ambrogio et al. NATURE MEDICINE
- Mutational landscape ofEGFR-,MYC-, andKras-driven genetically engineered mouse models of lung adenocarcinoma
- (2016) David G. McFadden et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets
- (2015) Matthias Drosten et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
- (2015) Frederick D. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Dragging Ras Back in the Ring
- (2014) Andrew G. Stephen et al. CANCER CELL
- The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
- (2014) Peter M. K. Westcott et al. NATURE
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
- (2013) Esther Castellano et al. CANCER CELL
- Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes
- (2013) Jehan J. El-Jawhari et al. MOLECULAR IMMUNOLOGY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction
- (2013) F. Shima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D
- (2011) Florian A. Karreth et al. Cancer Discovery
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Raf-1 Addiction in Ras-Induced Skin Carcinogenesis
- (2009) Karin Ehrenreiter et al. CANCER CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started